missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD180 Polyclonal Antibody
Description
Despite its predicted molecular weight, RP105 often migrates at 95-105kDa in SDS-PAGE. A suggested positive control is human spleen tissue lysate. PA5-20250 can be used with blocking peptide PEP-0372.
CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size. CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1. Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.
Specifications
Specifications
| Antigen | CD180 |
| Applications | Immunohistochemistry, Western Blot |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% sodium azide |
| Gene | Cd180 |
| Gene Accession No. | Q62192, Q99467 |
| Gene Alias | CD180; CD180 antigen; CD180 molecule; F630107B15; LY64; Ly78; Ly-78; lymphocyte antigen 64; Lymphocyte antigen 78; lymphocyte antigen-64, radioprotective, 105kDa; MGC126233; MGC126234; radioprotective 105 kDa protein; RP105 |
| Gene Symbols | Cd180 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?